Top Markets
#1 MowCat MowCat +48.87%
#2 Velvet Velvet +25.75%
#3 Quack AI Quack AI +21.37%
#4 Derive Derive +19.45%
#5 SkyAI SkyAI +17.12%
#6 Bermuda Shorts Bermuda Shorts +15.70%
#7 Geodnet Geodnet +15.17%
#8 aPriori aPriori +11.70%
#9 Cross Cross +11.69%
#10 Audiera Audiera +11.35%
Coin of the day
MowCat MowCat
Settings
Language
ENGLISH
Currency
USD
Theme
Kiromic BioPharma, Inc. Kiromic BioPharma, Inc.

Kiromic BioPharma, Inc.

KRBP
Rank in Stocks #35637
Kiromic BioPharma, Inc. is a biotechnology enterprise that harnesses artificial... Kiromic BioPharma, Inc. is a biotechnology enterprise that harnesses artificial intelligence to advance allogeneic cell therapies. The company's core mission involves crafting multi-indication T-cell treatments, specifically engineered to combat solid tumors by leveraging the innate capabilities of Gamma Delta T cells. Its developmental pipeline includes ALEXIS-ISO-1, an allogeneic gamma delta CAR-T cell therapy targeting Isomesothelin, and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy designed to address PD-L1. Supporting its research and development efforts, the company holds licensing agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, maintains a collaborative partnership for R&D with Molipharma, S.R.L., and has established a strategic alliance with Leon Office (H.K.) Ltd. Founded in 2006, the entity was initially known as Kiromic, Inc. before officially changing its name to Kiromic BioPharma, Inc. in December 2019. Its operations are headquartered in Houston, Texas.
Share Price
$0.11
Last synced: 2025-05-07
Market Cap
$3.62M
Change (1 day)
78.86%
Change (1 year)
0.00%
Country
US
Trade Kiromic BioPharma, Inc. (KRBP)

Category

Healthcare
P/E ratio for Kiromic BioPharma, Inc. (KRBP)
P/E ratio as of 2026 TTM: 0
According to Kiromic BioPharma, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Kiromic BioPharma, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 18.38 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.